Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

Aeterna Zentaris stock traded down $0.65 during mid-day trading on Friday, reaching $5.28. The company had a trading volume of 5,539 shares, compared to its average volume of 7,339. The stock’s 50-day simple moving average is $6.20 and its 200-day simple moving average is $7.28. The company has a market capitalization of $9.45 million, a P/E ratio of -0.35 and a beta of 1.55. Aeterna Zentaris has a 1 year low of $3.96 and a 1 year high of $12.36.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) EPS for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.